Melissa O’Gorman
Stamford Hospital(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Advanced Breast Cancer Therapies, Pharmacogenetics and Drug Metabolism, Colorectal Cancer Treatments and Studies, HER2/EGFR in Cancer Research
Most-Cited Works
- → Impact of Acid‐Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH‐Dependent Solubility, With Different Food Intake Conditions(2017)78 cited
- → A Highly Selective, Non-Hydantoin, Non-Carboxylic Acid Inhibitor of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one(2003)68 cited
- → A Novel Series of Non-Carboxylic Acid, Non-Hydantoin Inhibitors of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and Congeners(2005)65 cited
- → Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects(2014)56 cited
- → The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers(2020)53 cited
- → The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus(2017)47 cited
- → Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects(2014)45 cited
- → Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites(2021)38 cited
- → The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects(2015)35 cited
- → Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study(2021)34 cited